Follow
Mary Olson
Mary Olson
Associate Professor of Economics, Tulane University
Verified email at tulane.edu - Homepage
Title
Cited by
Cited by
Year
Regulatory agency discretion among competing industries: inside the FDA
MK Olson
The Journal of Law, Economics, and Organization 11 (2), 379-405, 1995
1381995
Are novel drugs more risky for patients than less novel drugs?
MK Olson
Journal of Health Economics 23 (6), 1135-1158, 2004
1232004
Substitution in regulatory agencies: FDA enforcement alternatives
M Olson
The Journal of Law, Economics, and Organization 12 (2), 376-407, 1996
1111996
Firm characteristics and the speed of FDA approval
MK Olson
Journal of Economics & Management Strategy 6 (1), 377-401, 1997
1011997
The risk we bear: the effects of review speed and industry user fees on new drug safety
MK Olson
Journal of health economics 27 (2), 175-200, 2008
972008
Pharmaceutical policy change and the safety of new drugs
MK Olson
The Journal of Law and Economics 45 (S2), 615-642, 2002
852002
Agency rulemaking, political influences, regulation, and industry compliance
MK Olson
Journal of Law, Economics, and Organization 15 (3), 573-601, 1999
811999
Managing delegation in the FDA: reducing delay in new-drug review
MK Olson
Journal of Health Politics, Policy and Law 29 (3), 397-430, 2004
592004
Regulatory reform and bureaucratic responsiveness to firms: The impact of user fees in the FDA
MK Olson
Journal of Economics & Management Strategy 9 (3), 363-395, 2000
402000
Political influence and regulatory policy: the 1984 drug legislation
MK Olson
Economic Inquiry 32 (3), 363-382, 1994
221994
Explaining Reductions In FDA Drug Review Times: PDUFA Matters: There was little reduction in FDA review times until after the introduction of prescription drug user fees.
MK Olson
Health Affairs 22 (Suppl1), W4-S1-W4-S2, 2003
172003
Explaining regulatory behavior in the FDA: political control vs. agency discretion
MK Olson
Advances in the Study of Entrepreneurship, Innovation, and Growth 7, 71-108, 1996
171996
Examining firm responses to R&D policy: An analysis of pediatric exclusivity
MK Olson, N Yin
American Journal of Health Economics 4 (3), 321-357, 2018
162018
Eliminating the US drug lag: implications for drug safety
MK Olson
Journal of Risk and Uncertainty 47, 1-30, 2013
162013
How have user fees affected the FDA
MK Olson
Regulation 25, 20, 2002
162002
PDUFA and initial US drug launches
MK Olson
Mich. Telecomm. & Tech. L. Rev. 15, 393, 2008
122008
Political influence and the development of US regulatory policy: the 1984 drug legislation
M Olson
Center for Economic Policy Research, Stanford University, 1991
71991
Stanford Research Workshop on the Pharmaceutical Industry: Summary of Presentations and Lead-Off Discussants
L Cabral, R Noll, M Olson, E Steinmueller
CEPR Publication 206, 1990
71990
New clinical information and physician prescribing: How do pediatric labeling changes affect prescribing to children?
MK Olson, N Yin
Health Economics 30 (1), 144-164, 2021
42021
Which Factors Shape and Limit the Role of the Center for Drug Evaluation and Research’s Advisory Committees?
S Schulman, MK Olson, RW Makuch
Drug information journal: DIJ/Drug Information Association 36, 281-289, 2002
42002
The system can't perform the operation now. Try again later.
Articles 1–20